Cargando…
Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients
AIM OF THE STUDY: Intrahepatic covalently closed circular DNA (cccDNA) is the main cause of hepatitis B virus (HBV) persistence. Therefore, a noninvasive serum biomarker that can reflect intrahepatic cccDNA is required for evaluation of HBV virological, biochemical activity and therapeutic response....
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122096/ https://www.ncbi.nlm.nih.gov/pubmed/34027120 http://dx.doi.org/10.5114/ceh.2021.104472 |
_version_ | 1783692514361868288 |
---|---|
author | Elshayeb, Aymen Farid Abdrabu, Mohamed Gamal Asar, Sara Lotfy Abdelaziz, Mohamed Adel Abuelkheir, Hossam |
author_facet | Elshayeb, Aymen Farid Abdrabu, Mohamed Gamal Asar, Sara Lotfy Abdelaziz, Mohamed Adel Abuelkheir, Hossam |
author_sort | Elshayeb, Aymen Farid |
collection | PubMed |
description | AIM OF THE STUDY: Intrahepatic covalently closed circular DNA (cccDNA) is the main cause of hepatitis B virus (HBV) persistence. Therefore, a noninvasive serum biomarker that can reflect intrahepatic cccDNA is required for evaluation of HBV virological, biochemical activity and therapeutic response. Aim of the study was to assess serum hepatitis B pregenomic RNA in low viremia patients (HBV DNA < 2000 IU/ml) and high viremia (HBV DNA > 2000 IU/ml). MATERIAL AND METHODS: This study was carried out on two groups of chronic hepatitis B patients: group A – 40 patients with low viremia (HBV DNA < 2000 IU/ml); group B – 40 patients with high viremia (HBV DNA > 2000 IU/ml when diagnosed). They were assessed before treatment and after 6 months of treatment (entecavir 0.5 mg/24 h). Serum HBV pregenomic RNA was quantified using RT-PCR. RESULTS: Pregenomic RNA (pgRNA) was significantly lower in group A than in group B (before treatment). Moreover, it was significantly lower after 6 months of treatment than before treatment in group B. A significant positive correlation was observed between pgRNA and HBV DNA in groups A and B (before treatment); however, after 6 months of treatment of group B patients, although 35 patients had undetectable HBV DNA, they showed detectable levels of serum pgRNA and pgRNA > 4000 IU/ml was associated with virological and biochemical activity. CONCLUSIONS: Serum HBV pregenomic RNA might be a promising marker for assessment of HBV virological, biochemical activity and evaluating therapeutic responses. |
format | Online Article Text |
id | pubmed-8122096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-81220962021-05-21 Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients Elshayeb, Aymen Farid Abdrabu, Mohamed Gamal Asar, Sara Lotfy Abdelaziz, Mohamed Adel Abuelkheir, Hossam Clin Exp Hepatol Original Paper AIM OF THE STUDY: Intrahepatic covalently closed circular DNA (cccDNA) is the main cause of hepatitis B virus (HBV) persistence. Therefore, a noninvasive serum biomarker that can reflect intrahepatic cccDNA is required for evaluation of HBV virological, biochemical activity and therapeutic response. Aim of the study was to assess serum hepatitis B pregenomic RNA in low viremia patients (HBV DNA < 2000 IU/ml) and high viremia (HBV DNA > 2000 IU/ml). MATERIAL AND METHODS: This study was carried out on two groups of chronic hepatitis B patients: group A – 40 patients with low viremia (HBV DNA < 2000 IU/ml); group B – 40 patients with high viremia (HBV DNA > 2000 IU/ml when diagnosed). They were assessed before treatment and after 6 months of treatment (entecavir 0.5 mg/24 h). Serum HBV pregenomic RNA was quantified using RT-PCR. RESULTS: Pregenomic RNA (pgRNA) was significantly lower in group A than in group B (before treatment). Moreover, it was significantly lower after 6 months of treatment than before treatment in group B. A significant positive correlation was observed between pgRNA and HBV DNA in groups A and B (before treatment); however, after 6 months of treatment of group B patients, although 35 patients had undetectable HBV DNA, they showed detectable levels of serum pgRNA and pgRNA > 4000 IU/ml was associated with virological and biochemical activity. CONCLUSIONS: Serum HBV pregenomic RNA might be a promising marker for assessment of HBV virological, biochemical activity and evaluating therapeutic responses. Termedia Publishing House 2021-03-25 2021-03 /pmc/articles/PMC8122096/ /pubmed/34027120 http://dx.doi.org/10.5114/ceh.2021.104472 Text en Copyright © 2021 Clinical and Experimental Hepatology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) ) |
spellingShingle | Original Paper Elshayeb, Aymen Farid Abdrabu, Mohamed Gamal Asar, Sara Lotfy Abdelaziz, Mohamed Adel Abuelkheir, Hossam Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients |
title | Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients |
title_full | Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients |
title_fullStr | Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients |
title_full_unstemmed | Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients |
title_short | Assessment of hepatitis B virus pregenomic RNA in high and low viremic chronic hepatitis B patients |
title_sort | assessment of hepatitis b virus pregenomic rna in high and low viremic chronic hepatitis b patients |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122096/ https://www.ncbi.nlm.nih.gov/pubmed/34027120 http://dx.doi.org/10.5114/ceh.2021.104472 |
work_keys_str_mv | AT elshayebaymenfarid assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients AT abdrabumohamedgamal assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients AT asarsaralotfy assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients AT abdelazizmohamedadel assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients AT abuelkheirhossam assessmentofhepatitisbviruspregenomicrnainhighandlowviremicchronichepatitisbpatients |